Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development

Name: Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development
Start: 2026-12-03T09:00
Location: Renaissance London Heathrow Hotel

Targeted Radiopharmaceuticals Summit EU 2026 · 3 December 2026 · 09:00

Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development was a session at Targeted Radiopharmaceuticals Summit EU 2026 on 3 December 2026 in London, with 1 speaker on record.

Speakers

Frederic Desdouits — Speaker Chief Executive Officer, OranoMed